Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| European Society of Intensive Care Medicine | OTHER |
| European Society of Clinical Microbiology and Infectious Diseases | OTHER |
| Institut National de la Santé Et de la Recherche Médicale, France | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Eurobact II will investigate the mortality and morbidity of hospital-acquired blood stream infections in patients treated in intensive care units (ICU). It will investigate the effects of the micro-organism and its characteristics, such as type and resistance to antibiotics on the infection and its consequences. It will also investigate the effects of the antibiotics and other treatments on survival of patients. Eurobact II will include patients from multiple ICUs in multiple countries.
Eurobact II is a multinational multicentre cohort study that will include patients with hospital-acquired blood stream infections (HA-BSI) treated in ICUs around the globe. It will provide with an update of the epidemiology of HA-BSI since the Eurobact I study. It is designed to investigate the effects of HA-BSI on mortality at day 28. To describe the determinants of outcomes of HA-BSI, specifically the effects of the source of infection, the microorganism, the characteristics of antimicrobial therapy and of source control. It will investigate patient specific and organizational factors and will describe the determinants of management of HA-BSI in ICUs.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HA-BSI | Patients with HA-BSI treated in an ICU |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | Vital status | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Progress of organ failures | Assessed by the components of the SOFA score | 7 days |
| Days free or organ supportive therapy | Days free of renal replacement therapy, mechanical ventilation, vasopressors, intensive care unit |
Not provided
Inclusion Criteria:
Age > 18 Years.
Hospital Acquired Bloodstream Infection (HA-BSI).
Treated in the ICU.
Exclusion Criteria:
Patients that had a positive blood culture in the hospital and transferred to ICU for a different reason than specific treatment of the causes or consequences of HA-BSI.
Previous inclusion in the study.
Not provided
Not provided
Not provided
Patients with a HA-BSI treated in an ICU
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alexis Tabah, MD | ICU, Redcliffe Hospital, Faculty of Medicine, UQ, Brisbane, QLD, Australia. | Principal Investigator |
| Jean-Francois Timsit, MD,PhD | Medical and infectious diseases ICU, Bichat hospital, IAME U 1137,Paris,France | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Redcliffe Hospital | Brisbane | Queensland | 4020 | Australia | ||
| Reanimation Medicale et Infectieuse-Hopital Bichat |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23011531 | Background | Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho F, Paiva JA, Cakar N, Ma X, Eggimann P, Antonelli M, Bonten MJ, Csomos A, Krueger WA, Mikstacki A, Lipman J, Depuydt P, Vesin A, Garrouste-Orgeas M, Zahar JR, Blot S, Carlet J, Brun-Buisson C, Martin C, Rello J, Dimopoulos G, Timsit JF. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012 Dec;38(12):1930-45. doi: 10.1007/s00134-012-2695-9. Epub 2012 Sep 26. | |
| 40192823 |
| Label | URL |
|---|---|
| Eurobact II website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 19, 2019 | May 1, 2019 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D016470 | Bacteremia |
| D018805 | Sepsis |
| D007049 | Iatrogenic Disease |
| D003428 | Cross Infection |
| ID | Term |
|---|---|
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
Not provided
Not provided
Not provided
Not provided
Not provided
| 28 days |
| Clinical cure | As evaluated by the treating clinician | 7 days, 28 days |
| Microbiological cure | Presence of persisting or relapsing blood stream infection | 7 days, 28 days |
| Paris |
| 75018 |
| France |
| Derived |
| Gajdos L, Buetti N, Tabah A, Ruckly S, Akova M, Sjoval F, Arvaniti K, de Waele J, Bracht H, Barbier F, Timsit JF; EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), the European Society of Clinical Microbiology, the Infectious Diseases (ESCMID) Study Group for Infections in Critically Ill Patients (ESGCIP) and the OUTCOMEREA Network. Shortening antibiotic therapy duration for hospital-acquired bloodstream infections in critically ill patients: a causal inference model from the international EUROBACT-2 database. Intensive Care Med. 2025 Mar;51(3):518-528. doi: 10.1007/s00134-025-07857-6. Epub 2025 Apr 7. |
| 36258239 | Derived | Buetti N, Tabah A, Loiodice A, Ruckly S, Aslan AT, Montrucchio G, Cortegiani A, Saltoglu N, Kayaaslan B, Aksoy F, Murat A, Akdogan O, Saracoglu KT, Erdogan C, Leone M, Ferrer R, Paiva JA, Hayashi Y, Ramanan M, Conway Morris A, Barbier F, Timsit JF; Eurobact 2 study group. Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: a descriptive analysis of the Eurobact II study. Crit Care. 2022 Oct 18;26(1):319. doi: 10.1186/s13054-022-04166-y. |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D020969 | Disease Attributes |